Home  |  Success Stories  |  Advising  |  Newsletter  |  Speaking  |  Articles  |  Seminars  |  Reports  |  Services  |  About Us  |  Contact Us    
FDA regulatory compliance consulting services - Cerulean weblogo
 


grayfade

 

Library of the SmarterCompliance Newsletter

To get access to the library and all the additional downloads, you must be a full subscriber.

Learn more about the benefits of a full SmarterCompliance subscription >>

Note:  all articles and downloads are in PDF format and will require the free Adobe Acrobat reader or similar.


2010 (vol.IV)

Issue Date

Content

August #44
  • Preparing for an Inspection, Part IV
  • Cost-Effective GCP Auditing
  • Trend Watch
  • Leadership Tips:  Using Subtlety
  • Book of Month:  How to Measure Anything
  • Bonus Online Content:
  • WHO pharmaceutical GMP distribution & traceability guidance
  • MHRA enforcement strategy
  • Proposed modifications to 45 CFR 160 & 164
  • PIC/S site master file guidance
  • ICH Q3D concept paper
  • ICH Q11 concept paper
  • Sgarlato FDA Form 483
July #43
  • Preparing for an Inspection, Part III
  • Nine Heparin Lessons
  • Trend Watch
  • Leadership Tips:  Setting Cross-Functional Goals
  • Book of Month:  Benjamin Franklin's 12 Rules of Management
  • Bonus Online Content:
  • FDA presentation on upcoming GMP revisions
  • FDA guidance on ISO 13485 audit submissions
  • GAO report on challenges with electronic data and records
  • Health Canada presentation on upcoming regulatory initiatives
  • Health Canada report on medical device inspection trends 2004-2009
  • IOM report, Ethical Issues in Studying the Safety of Approved Drugs
  • Congressional Letter to FDA Commissioner Hamburg
June #42
  • Preparing for an Inspection, Part II
  • Three-Batch Validation - Is it Obsolete?
  • Trend Watch
  • Leadership:  Building Trust
  • Book of Month:  Switch
  • Bonus Online Content:
  • FDA guidance Bioequivalence Recommendations
  • FDA Pre-Approval Inspection CPG manual 7346.832 (2010-2012)
  • FDA Post-Approval Inspection CPG manual 7346.843
  • FDA Drug Manufacturing Inspections CPG manual 7356.002
  • FDA QSIT guide
  • FDA Form 1572 FAQs
  • Quality Agreement Template
  • EMA GCP Ethical Reflection Paper
May #41
  • Conquering Regulatory Changes - Six Steps
  • Preparing for an Inspection, Part I
  • Trend Watch
  • Leadership:  Timing the Sharing of Information
  • Book of Month:  The Art of Possibility
  • Bonus Online Content:
  • GHTF draft guidance Label and Instructions for Use for Medical Devices
  • Comment form on draft guidance
  • GHTF guidance Post-Market Clinical Follow-Up Studies
  • GHTF guidance Clinical Investigations
  • FDA guidance Quality by Design and ICH Q8, Q9, Q10 FAQs
  • FDA presentation New Drug Benefit Risk Considerations
  • FDA presentation Regulatory Decision-Making
April #40
  • Outsourcing Trends 2010:  R&D and Virtual Suppliers
  • Clinical Patient Psychology (book excerpt)
  • Trend Watch
  • Leadership:  Going from "Me" to "We"
  • Fact Sheet:  Get to Market Now! Turn FDA Compliance into a Competitive Edge
  • Book of Month:  How to Work with the FDA
  • Bonus Online Content:
  • Outsourcing Trends 2010:  R&D and Virtual Suppliers (extended article)
  • MHRA Review of 2008-2009 GMP Deficiencies
  • Health Canada Proposed Equivalency Standards
March #39
  • Outsourcing Trends 2010:  RA and Quality
  • Training and Return on Investment
  • Trend Watch
  • Enforcement Analysis:  FDA's First Close Out Letter
  • Expert:  Clinical Site Financial Disclosure
  • Leadership:  Role Modeling for Followers
  • Book of Month:  The Truth About the New Rules of Business Writing
  • Bonus Online Content:
  • Outsourcing Trends 2010:  RA and Quality (extended article)
  • FDA Proposed Rules on Data Falsification
  • GAO Report on FDA and Increasing Executive Criminal Investigations
  • FDA Close Out Letter and Original Warning Letter
  • EMA Draft Revisions to GMPs on Quality Management Systems
  • EMA Inspectors Working Plans for 2010
  • Health Canada draft Guidelines for Follow-On Biologics (link only)
February
  • Challenges in Choosing an Auditor
  • Designing a Records Training Program
  • Trend Watch
  • Enforcement Analysis:  Drug and Biotech Warning Letter Trends 2007-2009
  • Expert:  Three Threshold Part 11 and Records Archival Questions
  • Leadership:  Managing Project Risk
  • Book of Month:  The Imposter
  • Bonus Online Content:
  • EMA Site Master File Guidance
  • FDA Bayesian Statistics Guidance
  • FDA Proprietary Drug Name Submissions Guidance
  • FDA cGMP Dissolution Calibration Guidance
  • Article on 28 Points to Consider in Clinical Trial Patient Privacy
  • Article on Device Reimbursement Considerations in Preclinical
January
  • Regulatory Submissions and Data Quality
  • Protecting Your Paper Records
  • Trend Watch
  • Enforcement Analysis:  Promotional enforcement trends
  • Expert:  Document management system service pack validation
  • Leadership:  Rapid Onboarding
  • Book of Month:  Use Both Sides of Your Brain
  • Bonus Online Content:
  • Inspector's Interpretations of EMA GMP Annex 1
  • FDA / ICH Nonclinical Safety Studies for Conduct of Human Clinical Trials
  • Draft Revised EMA GMP on Quality Management Systems

2009 (vol.III)

Issue Date

Content

December -2009
  • Regulatory Outlook and Forecast for 2010
    • General FDA forecasts
    • Enforcement expectations
    • Guidance documents expected
    • Longer-term (2011 and beyond) outlook
  • Book of Month:  The Predictioneer's Game
  • Bonus Online Content:
  • Annual trend watch and recommendations roundup (p. 9-19)
  • Transatlantic Administration Regulatory Harmonization Action Plan
  • Get to Market Now! excerpt
November -2009
  • Compliance Intelligence, Know-How & Staffing
  • Five Compliance Program Mistakes to Avoid
  • Trend Watch
  • Enforcement Analysis:  Adverse Event Reporting Warning Letter Citations
  • Expert:  Part 11 and Anti-Virus Software
  • Leadership:  Year-End Budgeting Tips
  • Book of Month:  Fundamentals of US Regulatory Affairs
  • Bonus Online Content:
  • Compliance Intelligence, Know-How & Staffing (cont'd, p. 9-11)
  • EMEA concept paper on revisions to Chapter 7 covering CMO qualification
  • GAO report on FDA device inspection trends
  • HHS report on FDA's handling of adverse event reports
  • Health Canada's draft guidance on GLP data
  • FDA guidance on clinical investigator responsibilities and delegation
  • Personal year-end closeout checklist
October-2009
  • Two FDA Officials on Supplier Qualification and Management Expectations
  • Self-Centered Compliance
  • Trend Watch
  • Enforcement Analysis:  FDA Sterilization
  • Expert:  Part 11 Status
  • Leadership:  Driving Decisions in Meetings
  • Book of Month:  Fierce Leadership
  • Bonus Online Content:
  • Two FDA Officials on Supplier Controls (cont'd, p. 9-11)
September-2009
  • Former FDA Prosecutor on Document Mistakes
  • Controlling Data Integrity for the FDA
  • Trend Watch
  • Enforcement Analysis:  FDA sampling expectations
  • Expert:  Generation considerations for inspections
  • Leadership:  30 minutes to better priorities
  • Book of Month:  The Future Arrived Yesterday
  • Bonus Online Content:
  • Former FDA Prosecutor interview (cont'd, p. 9-12)
  • Competitive Institute Comments on Draft Guidance on Risk Information
August-2009
  • 17 Lessons from the KV Pharmaceuticals Consent Decree
  • Steps to Qualify Virtual Suppliers of Raw Materials
  • Trend Watch
  • Enforcement Analysis:  FDA CAPA expectations
  • Expert:  Dealing with increased FDA stringency for enforcement
  • Leadership:  Tips on turning meetings into action items
  • Book of Month:  Lean for Dummies
  • Bonus Online Content:
  • 17 Lessons from the KV Pharma Consent Decree (cont'd, p. 9-14)
  • KV Pharmaceuticals Consent Decree
  • KV Pharmaceuticals FDA Form 483
  • EMEA Human Biosimilar Guideline
  • ICH E16 Genomic Biomarker Submissions
July-2009
  • Qualifying Virtual Consultants and Teleconsultants
  • Quality by Design and Regulatory Submissions
  • Trend Watch
  • Enforcement Analysis:  Training effectiveness and warning letters
  • Expert:  Accounting for clinical trial underreporting in regulatory submissions
  • Leadership:  Tips on improving your presentations and training
  • Book of Month:  On Managing Through a Downturn
  • Bonus Online Content:
  • Qualifying Virtual Consultants (cont'd, p. 9-14)
  • Health Canada's new GMPs for 2009
June-2009
(free issue #1)
  • Developing an FDA Records Discovery Strategy
  • An Analysis of FDA's 5-Year PDUFA Plan:  Where are We?
  • Trend Watch
  • Enforcement Analysis:  Contract supplier audits
  • Expert:  Retaining biosamples
  • Leadership:  Boosting employee compliance buy-in
  • Book of Month:  The Future of Medicine
  • Bonus Online Content:
  • FDA PDUFA 5-Year Plan
  • EMEA Guidance:  ICH Q8, Q9, Q10 Questions & Answers
  • EMEA Guidance:  GCP Inspection Coordination
  • FDA Discovery Strategy (cont'd, p. 9-16)
  • Sedona Principles on E-Discovery
  • Sedona Commentary on Records Litigation Holds
  • Excerpts of the FRCP Amendments and Advisory Committee Comments
May-2009
(free issue #1)
  • Managing Records in the Lab
  • FDA Compliance:  Where Do We Go from Here?
  • Trend Watch
  • Enforcement Analysis:  Data required to support efficacy and superiority claims
  • Expert:  Fun with process mapping
  • Leadership:  Minimizing outsourcing risk
  • Book of Month: The Fiefdom Syndrome
  • Bonus Online Content:
  • FDA Guidance:  OTC Drug Labeling (Small Business Series)
  • FDA Guidance:  Label Readability (draft)
  • GHTF Guidance:  Post-Market Clinical Follow-Up Studies
  • Untitled Letter:  Sanofi-Aventis Taxotere
Apr-2009
  • Ten Signs Potential FDA Trouble for You is Ahead
  • Personalized Medicine and Compliance Costs - Part Four: Knowledge, Information and Innovation
  • Trend Watch
  • Enforcement Analysis:  Clinical Sponsor Warning Letter Break-down
  • Expert:  Post-Approval CMC Guidance from FDA
  • Leadership:  Encouraging Accountability
  • Book of Month: Management Challenges for the 21st Century
  • Bonus Online Content:
  • Part Four (cont'd):  Personalized Medicine and Compliance Costs (p. 9-19)
  • FDA Guidance:  Exploratory IND Studies (Phase 0 Clinical Studies)
  • Health Canada Guidance:  CMC Quality in Clinical Trial Applications
Mar-2009
  • Six Costly IT Compliance Mistakes
  • Personalized Medicine and Compliance Costs - Part Three: University Collaborations in Developing Personalized Medicines
  • Trend Watch
  • Enforcement Analysis:  Q1 2009 Warning Letters
  • Expert:  GLP Enforcement by FDA
  • Leadership:  Progressive Discipline Policies
  • Book of Month: Revolutionary Wealth
  • Bonus Online Content:
  • Part Three: Universities and Personalized Medicine (p. 9-17)
  • GHTF Guidance:  Supplier Product and Services Controls
  • GHTF Guidance:  Registration of Manufacturers
Feb-2009
  • Insider Information Theft
  • Personalized Medicine and Compliance Costs - Part Two
  • Trend Watch
  • Expert:  Scheduling Product Development "Go/No-Go" Decisions
  • Leadership:  Improving Presentation Impact
  • Book of Month: Out of Our Minds - Learning to be Creative
  • Bonus Online Content:
  • Part Two: Personalized Medicine Compliance Cost Strategies (pages 7-13)
  • FDA Guidance:  Good Importer Practices
Jan-2009
  • Integrating IT, Quality and Regulatory Affairs
  • Personalized Medicine and the Cost to Compliance - Part One
  • Trend Watch
  • Expert:  Top Compliance Worries of 2009
  • Leadership:  Budget Reviews
  • Book of Month: The Regulatory Challenge of Biotechnology
  • Bonus Online Content:
  • Part One: Personalized Medicine and the Cost to Compliance (pages 7-17)
  • Virtualization and Validation: An Analysis


2008 (vol.II)

Issue Date

Content

Dec-2008
  • Tackling Today's Challenges - Five Tips
  • 2009:  A Look Ahead at the FDA
  • Trend Watch
  • Expert:  More tips to save money on audits
  • Leadership:  Closing out the year
  • Book of Month: The FDA and Worldwide Quality System Requirements Guidebook for Medical Devices
  • Bonus Online Content:
  • More 2009: A Look Ahead (with 34 more recommendations)
  • Year-end closeout checklist for busy executives
  • Quick summary of 2008 books of the month
Nov-2008
  • Ensuring Effective eCTD Submissions
  • Tripling your Audit Return on Investment
  • Trend Watch
  • Expert:  Assessing if your SOPs slow your business
  • Leadership:  Employee Efficacy
  • Book of Month: 7 Steps to Better Written Policies and Procedures
Oct-2008
  • Controlling Costs without Letting Results Slide
  • More Pharma Executives Lessons from the Courtroom
  • Trend Watch
  • Expert:  Quality by Design and Process Validation
  • Leadership:  The Cost of Employee Loss
  • Book of Month: The Halo Effect
Sep-2008
  • Intellectual Property Theft on the Rise
  • Confusion Over GMP Phase I Clinical Requirements
  • Trend Watch
  • Expert:  FDA Requires ICH Compliance
  • Leadership:  Busting Silos
  • Book of Month: Slack
Aug-2008
  • FDA Reform: What to Expect
  • Lessons You May Not be Learning from the Merck Vioxx Trials
  • Trend Watch
  • Expert:  FDA Guidance on Phase I
  • Leadership:  Avoiding Analysis Paralysis
  • Book of Month: Statistics for Six Sigma Made Easy
Jul-2008
  • Challenges of Quality by Design
  • PAT and Working with IT
  • Trend Watch
  • Expert:  Quality by Design and Biologics
  • Leadership:  Seeking the Big Picture
  • Book of Month: Getting Things Done
Jun-2008
  • FDA Warnings on Data Integrity
  • Foucault's Panopticon and Compliance
  • Trend Watch
  • Expert:  FDA's Focus on Executive Accountability and "Grain Size"
  • Leadership:  Using Statistics in Decision-Making
  • Book of Month: Predictably Irrational
May-2008
  • FDA Part 11 Revised
  • Six Pitfalls to Avoid in Supplier Management
  • Trend Watch
  • Expert:  Staying Compliant When You're a Small Business or Startup
  • Leadership:  Mapping Key Relationships
  • Book of Month: First, Break All the Rules
Apr-2008
  • Expedited Reviews and Quality by Design
  • Improving Compliance in an Economic Slowdown
  • Expert:  Post-Market Approval Burdens
  • Leadership:  Leading in a Crisis
  • Book of Month: Validation of Computerized Analytical and Networked Systems
Mar-2008
  • CDER and Quality by Design
  • How to Protect Your Records by Really Trying
  • Trend Watch
  • Expert:  "Silent" Medical Device Recalls
  • Leadership:  Getting Good Participation
  • Book of Month: The Lost Art of the Great Speech
Feb-2008
  • Generic Biologics:  How to Compete
  • Saving Intellectual Property
  • Trend Watch
  • Expert:  FDA Off-Label Guidance Impacts
  • Leadership:  Avoiding Overconfidence
  • Book of Month: New Drug Development: A Regulatory Overview
Jan-2008
  • Nonclinical Data Integrity
  • Annex to Q8: Quality by Design in Product Development
  • Trend Watch
  • Expert:  Piloting Six Sigma
  • Leadership:  CEO Tips on Knowing When to Ask for Advice
  • Book of Month: The Medical Device R&D Handbook


2007 (vol.I)

Issue Date

Content

Dec-2007
  • Six Tips to Better Annual Compliance Reviews
  • 2007 in the Rear View Mirror:  A Year-End Analysis of Trend Watch
  • Trend Watch
  • Expert:  Drawing the Line Between Fundamental R&D and Product Design
  • Leadership:  Making the Most of Coaching
  • Book of Month: Training for Dummies
Nov-2007
  • Modern Quality System Challenges
  • Lean Compliance - Part 2
  • Trend Watch
  • Expert:  When Suppliers Don't Want to Comply
  • Leadership:  Senior Team Morning Meetings
  • Book of Month: Made to Stick
Oct-2007
  • Compliance:  The Loss to Your Bottom Line (Lean Compliance - Part 1)
  • Preventing Intellectual Property Theft
  • Trend Watch
  • Expert:  Managing IT Change Control Smoothly
  • Leadership:  Conflict Resolution Tips
  • Book of Month: The Speed of Trust
Sep-2007
  • Postmarket FDA Surveillance:  The New Rules
  • Five Steps to Avoid Botching the Audit
  • Trend Watch
  • Expert:  Nano-Particle Labeling
  • Leadership:  Making Better Decisions
  • Book of Month: Design for Six Sigma
Aug-2007
  • Drug Safety Data - An Interview
  • Roadmap for Cost-Effective Part 11 Compliance
  • Trend Watch
  • Expert:  Pushing Back on Auditors
  • Leadership:  Managing a Crisis Well
  • Book of Month: Sun Tzu for Execution
Jul-2007
  • Addressing Information Integrity
  • Strategic Vendor Selection
  • Trend Watch
  • Expert:  Answering Auditor Questions
  • Leadership:  Running an Effective Meeting
  • Book of Month: Writing to Learn
Jun-2007
  • Analysis:  Quality by Design
  • Joint Development Agreements
  • Trend Watch
  • Expert:  Handling Costly Computer Validation "Solutions"
  • Leadership:  Effective Communication
  • Book of Month: Mind Set!
May-2007
  • Continuous Improvement Components
  • Financial Compliance Without Breaking the Bank
  • Trend Watch
  • Expert:  Dealing with Anxiety Around Audits
  • Leadership:  Tactics to Control Costs
  • Book of Month: Six Thinking Hats
Apr-2007
  • Quality as a Competitive Advantage
  • Export Compliance Focus
  • Trend Watch
  • Expert:  Hiring a Good Consultant
  • Leadership:  Improving Decision Impacts
  • Book of Month: IT Governance
Mar-2007
  • Adapting to Global Competition
  • Guest Article:  Policies, Policies, Policies
  • Trend Watch
  • Expert:  Compliance and Your Board of Directors
  • Leadership:  Improving Clinical Study Approvals
  • Book of Month: The Starfish and the Spider
Feb-2007
  • FDA Enforcement Trends
  • Global Regulations Converge
  • Trend Watch
  • Expert:  Drug Disposal Ruling Impacts
  • Leadership:  Avoiding the Minutiae
  • Book of Month: Why Smart Executives Fail
Jan-2007
  • FDA Guidance Documents - A Strategic Opportunity
  • Four Tips to Control Compliance Costs
  • Trend Watch
  • Expert:  Getting FDA's Regional Office to Help
  • Leadership:  CEO Tips to Improve Oversight Boards
  • Book of Month: Blue Ocean Strategy